Health Innovation Technology Transfer, S.L.
  • Team
  • Clients
  • Services
    • Business Development
    • Market Access Strategy
    • Healthcare Planning
  • R&D
  • Fundació HiTT
  • News
  • Contact

The Start-up Graveyard

Posted on 13/05/202013/05/2020 by Maria Nieto

Across all industries 9 out of 10 start-ups will fail. This staggering statistic doesn’t exactly inspire confidence. In healthcare the failure-rate may not be as detrimental but remains cause for concern. Which begs the question: why do so many start-ups fail?

Posted in healthcare, hitt, market access, pharma

Two companies supported by HiTT get outstanding reward.

Posted on 24/02/202015/04/2020 by Maria Nieto

HiTT celebrates that Barcelona Activa recognizes Qbeast with an award for the best project of high technological impact and Hospital Vall d’Hebron obtains more than 1M€ benefit from the exploitation of a patent license.

Posted in healthcare, hitt, market access, research, technology

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs

Posted on 26/02/201915/04/2020 by Maria Nieto

Oriol Sola Morales has collaborated in the creation of an article about reimbursement decisions on new oncology drugs. You can access to the entire article in this link.

Posted in healthcare, Uncategorized

Big Data analytical tools project

Posted on 28/01/2019 by Maria Nieto

Health Innovation Technology Transfer (HITT) is working on the development of an European project in Big Data tools. This project tries to understand the needs of the professionals that use Big Data tools in its analytical procedures.

Posted in hitt, research, technology

New acquisition cost of Repatha

Posted on 25/10/2018 by Maria Nieto

Today we learn that Amgen is lowering the acquisition cost of Repatha by 60% in the US.

Posted in healthcare, pharma

Gene therapy: Will it deliver its commercial promise?

Posted on 18/04/201826/04/2018 by webmaster

On April 10th 2018, Goldman Sachs published “The Genome Revolution” report on gene therapy, in which its analyst posed the thought-provoking question: “is curing patients a sustainable business model?”

Posted in healthcare, pharma

Drugs in the graveyard increase costs

Posted on 22/03/201822/03/2018 by Oriol Solà-Morales

This week we learned that Merck & Co. was ending the Phase III APECS study of Verubecestat (formerly known as MK-8931) for the treatment of prodromal Alzheimer Disease. Yet another drug in AD graveyard!!

Posted in pharma

Health Literacy, the resist subject

Posted on 09/03/201809/03/2018 by webmaster

What is Health Literacy?

Posted in healthcare

Posts navigation

← Older posts
Newer posts →
Legal Notices
Cookies Policy
Privacy Policy

Health Innovation Technology Transfer, S.L.

This website uses cookies to improve your experience. We'll assume you accept this policy as long as you are using this websiteAcceptView Policy
This page uses cookies and other technologies so that we can improve your experience on our sites: More information about our cookies policy.